NasdaqGS:CRNXPharmaceuticals
A Look At Crinetics Pharmaceuticals (CRNX) Valuation After PALSONIFY’s EU Approval And Global Expansion Progress
Crinetics Pharmaceuticals (CRNX) has been in focus after the European Commission approved PALSONIFY, its once daily oral treatment for acromegaly, expanding access across the EU and reinforcing the company’s broader international rollout plans.
See our latest analysis for Crinetics Pharmaceuticals.
Crinetics’ share price has been under pressure recently, with a 90 day share price return of a 21.9% decline and a year to date return of a 16.5% decline, even as the 1 year total shareholder...